Intercell AG · Vienna Austria ·(Pink Sheets: INRLF)(Vienna: ICLL)
Company Description
View Intercell AG Locations On A US Map
This link will open in a new window
This link will open in a new window Intercell AG really wants give the pharmaceutical industry a shot in the arm. The Austrian company develops new vaccinations that aim to invoke strong immune system responses. It sells a travelers vaccine for Japanese encephalitis in areas of Europe, the Asia/Pacific region, and North America. Vaccine development candidates aim to fight staph infections, pandemic influenza, hepatitis C, and other viral and bacterial infections. The company also develops antibody (protein) therapies. Intercell has commercial licensing and co-development agreements with larger companies, including Novartis , Sanofi-Aventis , and Merck . To read the full description, subscribe now.
Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!
Intercell AG Executives
14 executives listed for Intercell AG's Vienna, location.
| Title | Name & Bio | Contact |
| Chairman | Michel Gréco | Network |
| Vice Chairman | Ernst-Günter Afting | Network |
| CEO | Gerd Zeittlmeissl | Network |
Competition
Competitive Landscape for Intercell AG
Demand often depends on the income of consumers or the profitability of business customers, because many technology products and services are expensive. The profitability of individual companies is driven by their ability to develop and market new products. Large companies often have advantages in access to capital and marketing. Small companies can compete successfully if they have expertise in a particular field of knowledge. The industry is capital-intensive: average annual revenue per worker is nearly $300,000. To read the full description, subscribe now.Top Intercell AG Competitors
Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!